

# Amended Safety Assessment of Methylchloroisothiazolinone and Methylisothiazolinone as Used in Cosmetics

International Journal of Toxicology  
2021, Vol. 40(Supplement 1) 205–33S  
© The Author(s) 2021  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/10915818211016382  
journals.sagepub.com/home/ijt  


Christina L. Burnett\*, Wilma F. Bergfeld\*\*, Donald V. Belsito\*\*,  
Curtis D. Klaassen\*\*, Daniel C. Liebler\*\*, James G. Marks, Jr.\*\*\*,  
Lisa A. Peterson\*\*, Ronald C. Shank\*\*, Thomas J. Slaga\*\*,  
Paul W. Snyder\*\*, and Bart Heldreth†

## Abstract

The Expert Panel for Cosmetic Ingredient Safety (Panel) reassessed the safety of the mixture Methylchloroisothiazolinone (MCI)/Methylisothiazolinone (MI), which functions as a preservative in cosmetic products. The Panel reviewed relevant animal and human data provided in this safety assessment, and data from the previously published safety assessment of this mixture, and concluded that MCI/MI is safe in cosmetics when formulated to be nonsensitizing, based on the results of a quantitative risk assessment or similar methodology; however, at no point should concentrations exceed 7.5 ppm in leave-on products or 15 ppm in rinse-off products.

## Keywords

safety, cosmetics, methylchloroisothiazolinone, methylisothiazolinone

## Introduction

This safety assessment is on the combination of Methylchloroisothiazolinone (MCI) and Methylisothiazolinone (MI) as used in cosmetics. In 1992, the original report on MCI/MI was published by the Expert Panel for Cosmetic Ingredient Safety (Panel) and concluded that this mixture may be “safely used in rinse-off products at a concentration not to exceed 15 ppm and in leave-on cosmetic products at a concentration not to exceed 7.5 ppm.”<sup>1</sup> The stated safe-for-use concentration refers to a mixture containing 76.7% MCI and 23.3% MI (roughly, 3:1). According to the Cosmetic Ingredient Review (CIR) procedures, the Panel evaluates the conclusions of previously issued reports. The Panel determined that this safety assessment should be reopened to reassess the conclusion based on the numerous sensitization studies and reports that have been published since 1992.

While defined as separate ingredients that function as preservatives in cosmetics in the web-based *International Cosmetic Ingredient Dictionary and Handbook* (WINCI; *Dictionary*),<sup>2</sup> MCI is only known to be used in concert with MI. This safety assessment does not directly address the safety of the cosmetic use of either ingredient alone; however in 2020, the Panel assessed the safety of MI formulated without MCI and concluded that MI (alone) is safe for use in rinse-off cosmetic products at concentrations up to 100 ppm (ie, 0.01%) and

safe in leave-on cosmetic products when they are formulated to be nonsensitizing, which may be determined based on a quantitative risk assessment (QRA) or similar methodology.<sup>3</sup>

This safety assessment includes relevant published and unpublished data that are available for each end point that is evaluated. Published data are identified by conducting an exhaustive search of the world’s literature. A listing of the search engines and websites that are used and the sources that are typically explored, as well as the end points that Panel typically evaluates, is provided on the CIR website (<https://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and-websites>; <https://www.cir-safety.org/supplementaldoc/cir-report-format-outline>). Unpublished data are provided by the cosmetics industry, as well as by other interested parties.

\* Cosmetic Ingredient Review Senior Scientific Analyst/Writer

\*\* Expert Panel for Cosmetic Ingredient Safety Member

\*\*\* Expert Panel for Cosmetic Ingredient Safety Former Member

† Cosmetic Ingredient Review Executive Director

## Corresponding Author:

Bart Heldreth, Executive Director, Cosmetic Ingredient Review, 1620 L Street, NW, Suite 1200, Washington, DC 20036, USA.

Email: [cirinfo@cir-safety.org](mailto:cirinfo@cir-safety.org)

## Chemistry

### Definition

Methylchloroisothiazolinone (CAS No. 26172-55-4) is the heterocyclic organic ingredient that conforms to the structure shown in Figure 1.<sup>2</sup>

Methylisothiazolinone (CAS No. 2682-20-4) is the heterocyclic organic ingredient that conforms to the structure shown in Figure 2.<sup>2</sup>

### Physical Properties

MCI/MI is readily miscible in water, lower alcohols, glycols, and other hydrophilic organic solvents.<sup>1</sup> This mixture is a clear, light amber liquid with a specific gravity of 1.19 (at 20 °C), a pH of 3.5 (as supplied), and a freezing point of -18 to 21.5 °C.

### Impurities

Dimethylnitrosamine was reported to be formed as a reaction by-product at very low concentrations.<sup>1</sup> To limit the presence of this impurity, methyl-3-mercaptopropionate is added during production.

## Use

### Cosmetic

The safety of the cosmetic ingredients included in this assessment is evaluated based on data received from the US Food and Drug Administration (FDA) and the cosmetics industry on the expected use of these ingredients in cosmetics. Use frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in the FDA Voluntary Cosmetic Registration Program (VCRP) database. Use concentration data are submitted by the cosmetics industry in response to surveys, conducted by the Personal Care Products Council (Council), of maximum reported use concentrations by product category.

MCI and MI are reported to the VCRP separately and not as a mixture. According to 2019 VCRP survey data, the total number of uses reported for MCI is 5137; 480 of these are in leave-on products (Table 1).<sup>4</sup> MI has 6037 reported uses; 1042 of these are in leave-on products. The uses have increased significantly since the original report on MCI/MI was published; in 1986, the total number of uses reported for the ingredient mixture was 381.<sup>1</sup> In 2019, the Council reported that MCI/MI (3:1) is used at up to 7.5 ppm in leave-on products and at up to 15 ppm in rinse-off products.<sup>5</sup> In the original report, concentration of use was reported as a range; the concentration of use range for MCI/MI in both leave-on and rinse-off products was reported to be <0.1% to 1% (<1000-10000 ppm).<sup>1</sup>

MCI/MI may be used in products that can be incidentally ingested or come into contact with mucous membranes; for example, there are uses reported in lipsticks (reported in the VCRP only; concentration not reported), bath preparations (0.000019 ppm), and bath soaps and detergents (up to 15 ppm).<sup>4</sup>




Figure 1. Methylchloroisothiazolinone.




Figure 2. Methylisothiazolinone.

Additionally, this mixture has been reported to be used in products that may come into contact with the eyes; for example, these ingredients are reported to be used in eye makeup preparations (reported in the VCRP only; concentration not reported). Moreover, this mixture has been reported to be used in spray and powder products that could possibly be inhaled; for example, MCI and MI are reported to be used in colognes (0.075 ppm), hair sprays (7.5 ppm), and face powders (reported in the VCRP only; concentration not reported).

In the European Union, MCI/MI is listed under Annex V, the list of preservatives allowed in cosmetic products, with the restriction that the combination may be used at a maximum concentration of 0.0015% (ie, 15 ppm) in rinse-off products as a 3:1 ratio of MCI: MI.<sup>6</sup> The Scientific Committee on Consumer Safety (SCCS) in 2009 noted that MCI/MI is a well-recognized skin sensitizer at current conditions of use and concentration. The SCCS concluded that MCI/MI in a ratio of 3:1 does not pose a risk to the health of the consumer when used as a preservative at a maximum concentration of 0.0015% in rinse-off cosmetic products, apart from its sensitizing potential.<sup>7</sup> Induction and elicitation were considered less likely in a rinse-off product than when the same concentration is present in a leave-on product. In 2016, however, a proposal to amend Annex V to state that no safe concentrations for MI have been adequately demonstrated for use in leave-on cosmetic products

**Table 1.** Current (2019) and Historical (1986) Frequency and Concentration of Use According to Duration and Type of Exposure for Methylisothiazolinone and Methylchloroisothiazolinone.<sup>1,4,5</sup>

	# of Uses (2019)	# of Uses (2019)	Max Conc of Use (2019) (ppm)	# of Uses (1986)	Max Conc of Use (1986) (%)
	Methylchloroisothiazolinone*	Methylisothiazolinone*	MCI/MI <sup>‡</sup>	MCI/MI	MCI/MI <sup>‡</sup>
Totals <sup>†</sup>	<b>5137</b>	<b>6037</b>	<b>0.000019-15</b>	<b>381</b>	<b>&lt;0.1-1</b>
<i>Duration of Use</i>					
Leave-On	480	1042	0.021-7.5	137	<0.1-1
Rinse Off	4521	4849	0.15-15	244	<0.1-1
Diluted for (Bath) Use	136	146	0.000019	NR	NR
<i>Exposure Type</i>					
Eye Area	32	60	NR	8 <sup>d</sup>	<0.1-1 <sup>d</sup>
Incidental Ingestion	NR	1	NR	NR	NR
Incidental Inhalation-Spray	11; 192 <sup>a</sup> ; 112 <sup>b</sup>	14; 470 <sup>a</sup> ; 286 <sup>b</sup>	0.075-7.5; 7.4-7.5 <sup>a</sup>	5 <sup>a</sup> ; 95 <sup>b</sup>	<0.1-1 <sup>a,b</sup>
Incidental Inhalation-Powder	1; 112 <sup>b</sup> ; 2 <sup>c</sup>	1; 286 <sup>b</sup> ; 2 <sup>c</sup>	NR	95 <sup>b</sup>	<0.1-1 <sup>b</sup>
Dermal Contact	3486	4163	0.000019-15	178 <sup>d</sup>	<0.1-1 <sup>d</sup>
Deodorant (underarm)	NR	NR	NR	NR	NR
Hair—Non-Coloring	1567	1780	0.5-15	203 <sup>e</sup>	<0.1-1 <sup>e</sup>
Hair-Coloring	68	68	0.15-11	<sup>e</sup>	<sup>e</sup>
Nail	1	4	NR	NR	NR
Mucous Membrane	2981	3099	0.000019-15	8	<0.1-1
Baby Products	11	16	12	NR	NR

MCI = Methylchloroisothiazolinone; MI = Methylisothiazolinone; NR = Not reported; VCRP = Voluntary Cosmetic Registration Program.

\*MCI and MI are reported separately in the VCRP database. While it is likely that all MCI totals are for MCI/MI, there is no way to verify this information.

<sup>†</sup>Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

<sup>‡</sup>No wipe products were reported.

<sup>‡</sup>Concentrations were reported as general ranges in 1986.

<sup>a</sup>It is possible these products may be sprays, but it is not specified whether the reported uses are sprays.

<sup>b</sup>Not specified whether a powder or a spray, so this information is captured for both categories of incidental inhalation.

<sup>c</sup>It is possible these products may be powders, but it is not specified whether the reported uses are powders.

<sup>d</sup>Eye and facial makeup preparations were reported together in the original safety assessment. The reported number was only accounted for in the eye area exposure.

<sup>e</sup>Non-coloring and coloring hair preparations, except for non-coloring shampoos, were reported together in the original safety assessment. The reported number was only accounted for in the non-coloring hair products.

(including “wet wipes”) was announced, which would effectively ban MCI/MI from use in leave-on products.<sup>8</sup>

### Non-Cosmetic

MCI/MI (3:1) has been determined to be safe for use in indirect food additives as adhesive, coating, and paper and paperboard components only as an antimicrobial agent or a slimicide (21CFR §175.105, §175.300, §175.320, §176.170, and §176.300).

MCI/MI is reported to be used in water-based wall paints.<sup>9</sup> Analysis of 60 paint samples found the concentration of MCI to range from 0.5 to 3.5 ppm while the concentration of MI ranged from 1.1 to 142.7 ppm.

### Toxicokinetics

MCI/MI was absorbed after oral administration and then was excreted in the urine or feces; storage in the tissues was minimal. Up to 62% of a single percutaneous dose was bound to the site of application 24 hours after exposure. The MCI/MI bound to the skin had a 13.1-day half-life.<sup>1</sup>

In an oral metabolism study in humans, 4 volunteers received 2 mg of labeled 3-[<sup>13</sup>C]MI or 3-[<sup>3</sup>H]MCI (16.3 and 13 μmol, respectively) in 200 μL of ethanol in a glass of water, separately and at least 2 weeks apart.<sup>10</sup> Over a 48-hour period, consecutive and complete urine samples were collected and examined for the content of *N*-methylmalonic acid (NMMA). NMMA represented 23.7% and 13.3% of the dose excreted in urine after exposure of MI and MCI, respectively, with more than 90% excreted within the first 24 hours. Excretion of NMMA was rapid with mean half-lives of 6.1 and 7.6 hours for MI and MCI, respectively.

### Toxicological Studies

MCI/MI was moderately to highly toxic to rats, and highly toxic to rabbits when administered orally, and moderately toxic when applied dermally.<sup>1</sup> No treatment-related effects were observed in rats which received MCI/MI in oral doses up to 24.4 mg/kg/d for 2 weeks. Doses of MCI/MI up to 2.8 mg/kg/d applied dermally to rabbits, 5 d/wk for 3 weeks, produced moderate irritation at the application site but no systemic toxicity. Dermal application of MCI/MI at doses up to 0.4 mg/kg/d for 3 months produced no systemic toxicity in rabbits. No

toxicologically significant treatment-related effects were observed in dietary studies of rats or dogs at doses up to 30 and 28 mg/kg/d, respectively.

### Short-Term Toxicity Studies

**Oral.** In a 28-day repeated-dose oral study, male and female rats received MCI/MI (1.3%:0.38%) diluted in corn oil via gavage at 0, 0.26, 0.78, 2.3, and 7.0 mg/kg bw/d.<sup>11</sup> Water and feed consumption were monitored during the dosing period. At study end, the rats were killed, organs were weighed, and histological examinations were performed. Hematology, serum clinical chemistry, and biomarkers of inflammation were also assessed. No treatment-related effects on weight gains, organ weight, or hematological parameters were observed. A reduction of serum triglyceride levels in males and induction of hepatic phase 1 xenobiotic metabolizing enzymes in females, with subtle histological changes in the liver, were observed in the 7.0 mg/kg dose group. The authors stated that these changes were likely an adaptive, reversible response. The lowest-observed-effect-level (LOEL) was determined to be 7.0 mg/kg bw/d.

### Subchronic Toxicity Studies

**Inhalation.** In a 13-week repeated-dose inhalation study performed in accordance with Organization for Economic Co-operation and Development (OECD) test guideline (TG) 413, groups of 16 CrI: CD(SD)BR rats per sex were exposed to 14% MCI/MI.<sup>12</sup> The rats were exposed whole body for 6 hours per day, 5 day per week, at aerosol concentrations of 0, 0.34, 1.15, or 2.64 mg active ingredient (ai)/m<sup>3</sup>, with an aerosol particle size of 1.1 to 1.4 μm (mean mass median diameter), which is defined as the diameter at which 50% of the particles by mass are larger and 50% are smaller). During the exposure period, the rats were observed for clinical signs of toxicity, and body weight and ophthalmologic evaluations were made. At study termination, hematology, clinical chemistry, gross pathology, and histopathologic evaluations were conducted. No statistically significant effects were observed in the hematology, gross pathology, or ophthalmologic evaluations at any concentration. At 2.64 mg/m<sup>3</sup>, rats of both sexes had signs consistent with exposure to a sensory irritant, including chromorhinorrhea, rhinorrhea, eye squint, bradypnea, and dyspnea. Decreased body weight gains, decreased male spleen weights, and decreased serum protein in females were also observed in rats exposed to 2.64 mg/m<sup>3</sup>. No treatment-related clinical signs of toxicity, body weight effects, or organ weight effects were observed in the 0.34 or 1.15 mg/m<sup>3</sup> dose groups. Treatment-related histopathologic findings consisting of slight to moderate incidences of eosinophilic droplets in the anterior respiratory mucosa of the nasal turbinates and slight rhinitis in the lining of the anterior portion of the nasal cavity were observed in the 2.64 mg/m<sup>3</sup> dose group. At 1.15 mg/m<sup>3</sup>, rhinitis was observed in rats of both sexes. No treatment-related histopathologic effects were observed in the 0.34 mg/m<sup>3</sup> dose group.

All histopathologic changes were minor, potentially reversible, and generally reflective of minimal tissue response to a very mild, low-grade respiratory irritant. Based on the occurrence of rhinitis, the LOEL was 1.15 mg/m<sup>3</sup> ai. The no-observable-effect-level (NOEL) was 0.34 mg/m<sup>3</sup> ai.

### Developmental and Reproductive Toxicity Studies

MCI/MI administered by gavage to pregnant rabbits (gestation days 6 through 18) at doses up to 13.3 mg/kg/d was toxic to the dam, embryo, and fetus; the compound was not teratogenic.<sup>1</sup> In pregnant rats (gestation days 5 through 15) that received MCI/MI at doses up to 15 mg/kg/d, toxicity was observed in the dams, but no treatment-related effects were noted in any of the reproductive parameters of the surviving dams and fetuses and no teratogenicity was observed.

### Genotoxicity

The result of genotoxicity testing of MCI/MI varied with the assay used.<sup>1</sup> Mutagenicity was observed in several Ames tests with and without metabolic activation, but no genotoxicity was observed in several in vitro mammalian cell assays. Results were mixed in a mouse lymphoma cell assay, with genotoxicity observed when there was no metabolic activation.

The mutagenicity of a trade name mixture containing MCI/MI (14% ai; 10% MCI; 3.4% MI) and 5 cosmetic products that contained the trade name mixture was studied in an Ames test using *Salmonella typhimurium* strain TA 100, with and without metabolic activation.<sup>13</sup> The cosmetic products were diluted in distilled deionized water and tested at up to 400 μL/plate; MCI/MI was tested at doses ranging from 0.00039 to 0.05 μL/plate. Three of the 5 products were direct acting mutagens, while the other 2 were too cytotoxic to determine mutagenicity. Metabolic activation reduced cytotoxicity but did not eliminate mutagenicity. Mutagenicity was also observed with MCI/MI, with and without metabolic activation, in a dose-dependent manner.

### Carcinogenicity

Dermal application of 400 ppm of 2.67% MCI/MI in distilled water, 3 times per week for 30 months, had no local or systemic tumorigenic effect in male mice.<sup>1</sup>

### Dermal Irritation and Sensitization

The dermal irritation of MCI/MI was concentration dependent in rabbits under occlusive patches, with 560 ppm being non-irritating, 2800 ppm being moderately irritating, and 5600 ppm being severely irritating.<sup>1</sup> In humans, MCI/MI was irritating in a dose-dependent manner, with 100 ppm essentially nonirritating, 200 ppm slightly irritating, and 400 to 800 ppm strongly irritating. MCI/MI is a sensitizer: The concentration of MCI/MI in cosmetic products which produced sensitization varies. The

available human sensitization test data at concentrations of 50 ppm and above gave mixed results. MCI/MI was not a sensitizer at a concentration of 15 ppm.

### Human

In a human repeated insult patch test (HRIPT) of a hand wash containing 12 ppm MCI/MI in 50 volunteers, applications of 0.2 mL were made directly on the back as open patches on an area of approximately 2 cm<sup>2</sup> for a dose of 1.2 µg/cm<sup>2</sup>.<sup>14</sup> No adverse effects were observed during the study and no irritation or sensitization was observed during induction or challenge.

### Phototoxicity

MCI/MI was not a photosensitizer at a concentration of 15 ppm in human volunteers.<sup>1</sup>

### Ocular Irritation

MCI/MI in an aqueous solution was not a cumulative ocular irritant when tested at 55 ppm in rabbits; it was corrosive when tested at 1.1% (11000 ppm and higher).<sup>1</sup>

### Clinical Studies

#### Provocative Studies

A repeated open application test (ROAT) was performed on 15 patients with known contact allergy to 100 ppm MCI/MI and/or MI (6 patients reacted to MCI/MI only, 6 patients reacted to MI only, and 3 patients reacted to both MCI/MI and MI).<sup>15</sup> Each patient was given 2 sets of aqueous skin creams. One cream contained MI at 100 ppm, while the other contained paraben preservatives. The patients applied the creams twice daily for 2 weeks to the outer aspect of the upper arm on an area of 25 cm<sup>2</sup>. The sites were evaluated by dermatologists prior to the ROAT commencement; after 1 and 2 weeks, 8 patients had positive allergic responses at the test sites who received the MI-containing creams. Of the patients with the known MI allergy, 5 had positive responses. Of the patients with the known MCI/MI allergy, 6 had positive responses.

Baseline series patch tests, photopatch tests, and/or phototests were performed on a total of 10 patients with suspected photoaggravated contact dermatitis to MCI/MI or MI.<sup>16</sup> All 10 patients underwent the baseline patch tests: The test concentrations for MCI/MI were 0.01% or 0.02% aq., and for MI was 0.2% aq. Six patients were photopatch tested with cosmetics containing MCI/MI and/or MI (amount of test substance not reported), with one of the 2 identical patches being irradiated with 5 J/cm<sup>2</sup> long-wavelength ultraviolet (UVA) light. Phototests were performed on 2 patients with UVA/mid-wave length ultraviolet radiation ranging between 290 and 400 nm. Seven patients had positive patch tests to both MCI/MI and MI, and 3 patients had positive patch tests to only MI. Four patients had transient photosensitivity. Photopatch tests with

MCI/MI and/or MI gave stronger reactions than baseline patch tests with these ingredients, indicating photoaggravation.

### Baseline and Retrospective Studies

*Dermal.* Numerous baseline and retrospective studies which included testing with MCI/MI have been published since the original report was issued; a sampling of these studies is presented in Table 2. The results of these studies demonstrate that sensitization to MCI/MI is found worldwide, with reported rates as low as 0.7% (out of 703 patients; United States) to as high as 15.4% (out of 635 patients; Thailand).<sup>17-50</sup>

### Case Reports

Cases studies include reports of MCI/MI sensitization from a wide range of materials, including personal care products (including wet wipes), ultrasound gels, paints, glues, cleaners, and industrial biocides.<sup>51-68</sup> Dermal sensitization from paint was hypothesized to be from airborne exposure in several patients.<sup>56,58,63,64</sup>

### Airway Dysfunction

Peripheral airway dysfunction was observed in a retrospective assessment of 24 children in South Korea, with no underlying disease, who were exposed to MCI/MI as a humidifier disinfectant (HD).<sup>69</sup> The children were exposed to MCI/MI at high density for up to 6 months and were exposed initially as infants. Pulmonary function was assessed with impulse oscillometry. One child died at age 4 month after continuous use of the HD over 3 months.

In a related study of 530 registered patients with lung disease who were exposed to HDs in South Korea, 3 definite or probable cases of airway dysfunction were reported from use of an HD that contained MCI/MI (127 mg/L MCI:37 mg/L MI).<sup>70</sup> Two of these cases were in infants, and 1 was in an adult patient who died. Another 33 cases of airway dysfunction were possibly or unlikely/intermittently associated with the HD containing MCI/MI; 5 deaths were reported in these cases.

Case studies from South Korea related to exposure of an HD containing MCI/MI, resulting in lung injury, included a set of twin girls who were exposed from ages 4 to 6 months, and another girl who was exposed from age 11 to 25 months.<sup>71,72</sup> The twin girls presented with cough, sputum, and respiratory difficulty, and were observed with pneumomediastinum on chest X-ray.<sup>71</sup> In the latter case, the patient presented with coughing, fever, dyspnea, and tachypnea that progressively worsened and she developed acute respiratory distress syndrome: The patient died during hospitalization.<sup>72</sup>

### Risk Assessment

A skin sensitization induction risk assessment of MCI/MI was performed with various personal care products.<sup>73</sup> An estimated daily consumer exposure level (CEL) for rinse-off and leave-on products was calculated using the amount of product applied

**Table 2.** Baseline and Retrospective Studies.

Number of Patients	Clinical Testing Type	Country and Time Span	Results	Reference
5899 patients	Swedish baseline patch test series using Finn Chambers secured with Scanpor tape; 15 µL of 0.02% aq. MCI/MI (200 ppm; 3:1) and serial dilutions of MI alone	Southern Sweden; March 2003-December 2012	184 patients (3.1%) reacted to MCI/MI, with a notable increase in frequency from 4.3% in 2010 to 7.6% in 2012	17
141 recently diagnosed with sensitivity to 0.02% aq. MCI/MI	Tested MCI (0.015%) and MI (0.005%) separately with simultaneous application of haptens (0.2 mL); patches were Haye test chambers with Soffix tape; occluded for 2 days	8 clinics in Italy; January 2016-December 2016	110 patients (78.1%) reacted to MCI, of which 60 (42.6%) reacted only to MCI and 50 (35.5%) reacted to both MCI and MI	18
229 children (96 were 7 years old and 133 were 16 years old) identified as having eczema through an allergy screening survey	Patch testing with 10 most common contact sensitizers in children in Europe; MCI/MI tested at 0.01% aq. with Chemotechnique IQ Ultra Chambers for 2 days	Poland; 2007	6.3% of 7-year-olds and 0.8% of 16-year-olds had a positive reaction to MCI/MI	19
14274 work-related contact dermatitis cases	Baseline series of the British Society of Cutaneous Allergy; MCI/MI tested a 0.01% aq. until 2008, then changed to 0.02% aq.	United Kingdom; 1996-2012	4.1% (358) patients per annum had dermatitis attributed to MCI/MI; occupations of affected workers included beauty workers, hairdressers, health-care workers, cleaners exposed to detergents, painters, manufacturing, and other industrial work.	20
3201 with either widespread or localized dermatitis	European baseline series and international standard series along with patients' products; MCI/MI was tested at 0.02% aq.; patches were Finn chambers applied for 2 days	Thailand; January 2005-December 2016	15.4% (98/635) patients with widespread dermatitis and 9.1% (204/2244) patients with localized dermatitis reacted to MCI/MI	21
4860 patients	Patch tested with screening series of 70 allergens, including 0.01% MCI/MI aq. and 0.2% MI aq.; patches were Finn chambers on Scanpor tape	13 centers from the North American Contact Dermatitis Group (NACDG); January 2013 to December 2014	6.3% (305) patients had positive reaction to MCI/MI, a significant increase from the previous testing cycle (5.0%; 2011-2012); 10.9% (527) patients had positive reaction to MI	22,23
124 patients with long-lasting perianal dermatitis	Patch tests with Spanish research group standard series, and depending on patient clinical history, more specific test series and suspected personal products; patch test was occluded for 2 days; additional diagnostic protocols including biopsies and cultures were performed	Spain; April 2004 to August 2016	13.7% (17/124) of patients reacted to MCI/MI	24
2315 patients	Baseline patch tests series with 0.02% MCI/MI aq.	2 centers in the United Kingdom; August 2011 to June 2013	9.4% (217/2315) of patients reacted to MCI/MI	25
997 patients	British baseline patch tests series with 0.02% MCI/MI aq.	United Kingdom; January to December 2015	3.9% of patients reacted to MCI/MI, this was a decrease from 7.9% in 2014	26
44 patients identified through a survey as having airborne allergic contact dermatitis caused by paint	Tested with 0.02% and/or 0.01% MCI/MI aq. and 0.02%, 0.05%, and 0.2% MI aq.	17 dermatology departments and 2 private offices in France and Belgium; survey occurred May 2015 to May 2016 with patients diagnosed from January 2012 to January 2016	36/44 (82%) patients had positive reactions to MCI/MI and 43/44 had positive reactions to MI	27

(continued)

Table 2. (continued)

Number of Patients	Clinical Testing Type	Country and Time Span	Results	Reference
206 patients	Standard series patch tests (39 allergens); patches were 8 mm Finn chambers on Scanpor tape; results read at 48 and 72 h	Thailand; 2012 to 2015	13.6% (28/206) of patients tested positive to 0.01% MCI/MI	28
324 patients	European baseline series with 0.02% MCI/MI aq. and 0.2% MI aq.; patches were IQ Ultra chambers and readings were day 2 and day 4	Turkey; January 2016 to June 2018	6.17% (20/324) of patients tested positive to MCI/MI; 8.02% of patients tested positive to MI	29
1287 patients	Baseline series with 0.02% MCI/MI aq., 0.2% MI aq., 0.1% benzisothiazolinone pet., and 0.1% octylisothiazolinone pet.; the occluded patches were IQ Ultra chambers and readings were on day 2 and day 4	United Kingdom; September 2014 to December 2015	9.2% (118) of patients had positive reactions to any isothiazolinone; cross-sensitization thought to occur between MCI/MI, MI, and octylisothiazolinone	30
703 patients	Retrospective review of patients tested with the North American Contact Dermatitis Group standard series; MCI/MI tested at 100 ppm and MI tested at 200 to 2000 ppm	United States; January 1, 2012 to December 30, 2014	0.7% (5) reactions to MCI/MI and 2.4% (17) reactions to both MCI/MI and MI	31
2703 patients	Testing in consecutive patients with 0.01% and 0.02% MCI/MI aq.; patches were 8 mm Finn chambers on Scanpor tape	8 centers in 8 countries that included Japan, Germany, Belgium, Sweden, Uruguay, India, Denmark, and Singapore; January 1, 2014 to December 31, 2014	3.7% and 5.6% of patients had reactions to 0.01% and 0.02% MCI/MI, respectively	32
2576 patients to MCI/MI and 964 to MI	Patients tested with Mayo Clinic Institution's standard series that included 0.2% MI aq. and 100 ppm MCI/MI aq.; patches were Finn chambers on Scanpor tape	Mayo Clinic; January 1, 2011 to December 31, 2015	5.9% and 13.6% of patients had allergic reactions to MCI/MI and MI, respectively	33
1745 patients	Retrospective study of patients tested with a modified Finnish baseline or antimicrobial series; 0.01% and 0.02% aq. MCI/MI, 0.1% and 0.03% aq. MI, 0.05% pet. benzisothiazolinone, and 0.1% pet. octylisothiazolinone; patches were Finn chambers occluded for 48 h	Finland; January 2002 to February 2013	2.6% and 0.2% of patients had allergic reactions to MCI/MI and MI, respectively	34
490 patients	Prospective study using the Spanish baseline series; 100 and 200 ppm aq. MCI/MI and 2000 ppm aq. MI; Finn chambers on Scanpor tape and occluded for 2 days	Spain; October 2011 to June 2013	10% and 4.5% of patients had reactions to MCI/MI and MI during the 2-year study; prevalence to MCI/MI allergy increased from 7.8% in 2011 to 14.3% in 2013 while prevalence to MI allergy increased from 1% to 7.7%	35
79 patients out of 9037 that had allergic reactions to a wipe	Retrospective analysis of patients patch tested to a screening series of 70 allergens; MCI/MI tested at 0.01% aq. and MI tested at 0.2% aq.	13 centers from NACD; January 1, 2011 to December 31, 2014	59% of the patients who had reactions to wipes had a reaction to MI while 35.6% had reaction to MCI/MI	36
2165 patients	Patients tested with Swedish baseline series; 200 ppm aq. MCI/MI and 2000 ppm aq. MI; 8 mm diameter Finn chambers on Scanpor tape	Sweden; 2012 to 2014	8.1% (175) and 7.1% (153) of patients had reactions to MCI/MI and MI, respectively; 9.5% (206) of patients were found to have allergy to MCI/MI and/or MI	37
2028 patients	Patch testing in accordance with European Society of Contact Dermatitis guidelines; 0.2% aq MI and 0.01% aq. MCI/MI	Italy; January 2012 to December 2014	7.5% (152) and 5.2% (106) of patients had reactions to MCI/MI and MI, respectively	38
3253 patients	Patients tested with 100 ppm aq. MCI/MI and 2000 ppm aq. MI (only tested in 2014); Finn chambers under occlusive for 2 days	Thailand; January 2009 to June 2014	9.8% of patients had positive patch tests to MCI/MI; 40.7% (22/54) of patients had positive patch test to MI	39

(continued)

Table 2. (continued)

Number of Patients	Clinical Testing Type	Country and Time Span	Results	Reference
80 patients with facial dermatitis	Patients tested with British Society for Cutaneous Allergy (BSCA) standard series and their own cosmetic products; 0.02% MCI/MI and 0.2% MI	Ireland; January 2012 to March 2014	6.3% (5) and 5% (4) of patients tested positive to MCI/MI and MI, respectively	40
4094 patients	Patients tested with baseline patch test series; Finn chambers on Scanpor tape; test concentrations not reported	Switzerland; 2000 to 2004	2.1% (88) of patients tested positive to MCI/MI	41
964 patients	Retrospective review of patients tested with BSCA standard series and individualized additional test series; IQ ultra chambers for 48 h; 0.01% aq. or 0.02% aq. MCI/MI	Ireland; 2007 to 2010	2.2% (21/964) of patients tested positive to MCI/MI; of these, 1.6% (11/697) were positive to 0.01% and 3.8% (10/267) were positive to 0.02%	42
4227 patients	Patients patch tested with a screening series of 70 allergens; MCI/MI tested at 0.01% aq.; Finn chambers on Scanpor tape	12 centers from NACD; January 1, 2011 to December 31, 2012	5.0% (213) of patients tested positive to MCI/MI; prevalence of allergy had increased since the previous years (2001-2010)	43
219 painters with contact dermatitis	Retrospective study of European baseline series patch test results of all painters registered in the Danish National Database for Contact Allergy; MCI/MI tested at 0.01% aq.; MI, octylisothiazolinone, and benzisothiazolinone were also tested (concentrations not reported); patches occluded for 48 h	Denmark; 2001 to 2010	10% (22/219) of the painters tested positive to MCI/MI; 27% (11/41) tested positive to MI; 25% (5/21) tested positive to octylisothiazolinone; and 19% (7/37) tested positive to benzisothiazolinone	44
359 patients	Retrospective study of Brazilian standard series results; MCI/MI tested at 0.5% pet.	Brazil; November 2009 to October 2012	11.1% (40/359) of patients tested positive to MCI/MI; increase from previous study period (3.4% from 2006-2009)	45
14,693 patients	Retrospective study of European baseline series patch test results; test concentrations not reported	Hungary; 1993 to 2014	Prevalence of MCI/MI hypersensitivity increased from 0.5% (5/1011) of patients in 1993 to 6.0% (23/383) of patients in 2014	46
314 patients	Patients prospectively patch tested with 0.01% aq. MCI/MI and 0.2% aq. MI with parallel testing to the European baseline series with 0.01% aq. MCI/MI; IQ chambers and Curatest patches, respectively, and occluded for 48 h	Hungary; February 1, 2014 to January 30, 2015	5.1% (16/314) of patients were positive to MCI/MI and 4.8% (15/314) of patients were positive to MI; no differences between the patch series types	46
Up to 6722 patients	Retrospective study of patients; consecutively patch tested with 100 ppm aq. or 4 µg/cm <sup>2</sup> (TRUE test) MCI/MI, 200 or 2000 ppm aq. MI, and 500 or 1000 ppm aq. benzisothiazolinone; occluded 48 h	3 centers in Denmark; 2009 to 2012	3.2% (213/6722) of patients tested positive to MCI/MI, 3.2% (170/5290) tested positive to MI, and 0.9% (34/3636) tested positive to benzisothiazolinone	47
Up to 48720 patients	Retrospective study of data collected by the European Surveillance System on Contact Allergies (ESSCA) from European baseline series and other allergen testing; MCI/MI was tested at 0.01% and 0.02% aq. and MI was tested at 0.05%, 0.1%, and 0.2% aq.	54 centers in 12 European countries; January 2009 to December 2012	4.1% of patients were positive to 0.02% MCI/MI and 3.3% were positive to 0.01% MCI/MI; 4.5% of patients were positive to 0.05% MI, 0.21% were positive to 0.1% MI, and 4.9% were positive to 0.2% MI	48
45 children with atopic dermatitis (ages 2 mo to 17 years)	Patients tested with the TRUE patch test system; patch test plasters applied to upper back for 2 days; concentrations not reported	Turkey; September 2011 to March 2012	20% (9/45) of the patients had a positive reaction to MCI	49
7533 out of 20107 patients	Meta-analysis of 28 studies of the general population from studies written in English available on PubMed; patch tests were conducted with the European baseline series or something similar; concentrations of MCI/MI tested not reported	Various centers from Asia, Europe, North America, and Australia; 2007 to 2017	Prevalence of allergy is 1.5% (95% CI 0.8-2.5) in the general population based on 6 studies	50

MCI/MI = Methylchloroisothiazolinone/Methylisothiazolinone.



per application, number of applications per day, a retention factor, the MCI/MI concentration, and body surface area values. The researchers assumed that the products contained the maximum recommended safe concentration of 15 ppm MCI/MI in rinse-off products and 7.5 ppm MCI/MI in leave-on products. The estimated CELs were compared with the no-expected-sensitization-induction-level (NESIL) for MCI/MI of  $0.83\mu\text{g}/\text{cm}^2$ , which was based on the value reported by the SCCS from weight-of-evidence (WoE) data from an HRIPT. The sensitization assessment factors (SAFs) were applied to calculate product-specific margins of safety (MOSs). The researchers found that the MOSs for rinse-off products ranged from 5 to 63, whereas the MOSs for leave-on products ranged from 0.03 to 1.49. An MOS of 1 or greater indicates a low likelihood of sensitization induction. The researchers concluded that the results provide evidence that some leave-on products containing the maximum recommended safe concentration of MCI/MI may increase the risk of sensitization induction due to exposure to MCI/MI, while rinse-off products were not associated with a potential increased risk of skin sensitization induction.

In another skin sensitization risk assessment of MCI/MI, the maximum safe concentration of 15 ppm MCI/MI in representative-type cosmetics (which included shampoos, conditioners, soap, lotions, hand and face cream, deodorants, wipes, and eye and face makeup) indicated the possibility of skin sensitization when an NESIL of  $1.25\mu\text{g}/\text{cm}^2$  was used in the determination.<sup>74</sup> However, there was no potential for skin sensitization at this concentration for just rinse-off products. In this assessment, the MOS was calculated as the acceptable exposure level (AEL)/CEL and was considered safe when the AEL/CEL ratio was 1 or more. The AEL is calculated as the NESIL/skin SAF. For the representative type cosmetics, the SAF was 300; while in rinse-off products, it was 100. The MOS for representative type cosmetics was determined to be 0.00538 and the MOS for rinse-off products was 2.14.

In a QRA performed by the CIR Science and Support Committee (SSC), a conservative NESIL of  $0.83\mu\text{g}/\text{cm}^2$  was derived for MCI/MI based on a WoE evaluation of HRIPT data and data from local lymph node assays (LLNA).<sup>75</sup> The NESIL was then used to calculate AELs for the potential for the induction of sensitization from dermal exposure to MCI/MI in cosmetic products, assuming the maximal use concentration of 15 ppm for rinse-off products and 7.5 ppm for leave-on products and VCRP product category-specific QRA SAFs. The SAFs include 6 component factors (interindividual, site, skin condition, matrix, occlusion, frequency and duration of exposure). Individual CELs were then calculated for numerous VCRP product categories, ranging from baby shampoo (CEL =  $0.0024\mu\text{g}/\text{cm}^2$ ) to skin cleansing products (CEL =  $0.0135\mu\text{g}/\text{cm}^2$ ). The lowest CEL to MCI/MI was  $3.8 \times 10^{-9}\mu\text{g}/\text{cm}^2$  for bubble baths, and the highest estimated exposure was  $0.0315\mu\text{g}/\text{cm}^2$  for permanent waves. By using the maximum reported MCI/MI concentration of use levels provided by the Council survey (Table 3), an adequate MOS for skin sensitization is provided for all reported uses except for permanent

waves (using 7.5 ppm MCI/MI) and for skin cleansing products (ie, cold creams, cleansing lotions, liquids, and pads; using 15 ppm MCI/MI). The maximum supportable concentration of MCI/MI for permanent waves and skin cleansing products are 2 and 9 ppm, respectively. When using the exposure assumptions in this risk assessment on all reported VCRP product categories of use with the maximum recommended concentrations of use, as set by the original CIR conclusion, of 7.5 ppm in leave-on products and 15 ppm in rinse-off products (Table 4), an adequate MOS could not be assured for baby shampoo (MOS = 0.92), permanent wave (MOS = 0.13), hair tints (MOS = 0.56), skin cleansing products (0.61), or cologne and toilet waters (0.50).

## Summary

This safety assessment is for the combination of MCI and MI as used in cosmetics. Each ingredient is reported to function as a preservative in cosmetic products. In 1992, the original report on MCI/MI was published with the Panel's conclusion that this mixture may be "safely used in rinse-off products at a concentration not to exceed 15 ppm and in leave-on cosmetic products at a concentration not to exceed 7.5 ppm." The stated safe-for-use concentration refers to a mixture containing 76.7% MCI and 23.3% MI.

MCI and MI are surveyed separately in the VCRP and not as a mixture. According to 2019 VCRP survey data, the total number of uses reported for MCI is 5137; 480 of these are in leave-on products. MI has 6037 reported uses; 1042 of these are in leave-on products. The number of uses has increased significantly since the original report on MCI/MI was published; in 1986, the total number of uses for the ingredient mixture was 381. In 2019, the Council reported that MCI/MI (3:1) is used at up to 7.5 ppm in leave-on products and at up to 15 ppm in rinse-off products. In the original report, concentration of use was reported as a range; the concentration of use range for MCI/MI in both leave-on and rinse-off products was reported to be < 0.1 to 1%.

In the European Union, MCI/MI is listed as a preservative in Annex V; it is limited to a maximum concentration of 0.0015% (ie, 15 ppm) in rinse-off products as a 3:1 ratio of MCI: MI. The SCCS concluded in 2009 that MCI/MI in a ratio of 3:1 does not pose a risk to the health of the consumer when used as a preservative at a maximum concentration of 0.0015% in rinse-off cosmetic products, apart from its sensitizing potential. In 2016, however, a proposal to amend Annex V to state that no safe concentrations for MI have been adequately demonstrated for use in leave-on cosmetic products (including wet wipes) was announced, which would effectively ban MCI/MI from use in leave-on products. At that time, Annex V was amended to restrict the use of MI in rinse-offs to no more than 100 ppm, although the amendment to ban use in leave-ons was deferred.

MI and MCI were determined to metabolize into NMMA in humans after oral ingestion. Excretion of the metabolite through urine was rapid.

**Table 3.** Quantitative Risk Assessment of MCI/MI at the Highest Reported Maximum Use Concentrations in Cosmetic Products.<sup>75</sup>

Product Category	Reported Maximum Concentration of Use (ppm)	Weight of Evidence NESIL ( $\mu\text{g}/\text{cm}^2$ )	Sensitization Assessment Factor (SAF)	Acceptable Exposure Level (AEL; $\mu\text{g}/\text{cm}^2/\text{d}$ )	Consumer Exposure Level (CEL; $\mu\text{g}/\text{cm}^2/\text{d}$ )	Margin of Safety (AEL/CEL)
Baby shampoo	12	0.83	300	0.0028	0.0027	1.15
Bubble baths	0.000019	0.83	100	0.0083	$3.8 \times 10^{-9}$	>2000000
Cologne and toilet waters	0.075	0.83	100	0.0083	0.0002	50.07
Hair conditioners	15	0.83	100	0.0083	0.0030	2.77
Hair sprays (aerosol)	7.5	0.83	30	0.0277	0.0104	2.65
Hair sprays (pump)	7.5	0.83	30	0.0277	0.0163	1.70
Permanent waves	7.5	0.83	100	0.0083	0.0315	0.26
Rinses (non-coloring)	11	0.83	300	0.0028	0.0019	1.48
Shampoos (non-coloring)	15	0.83	300	0.0028	0.0026	1.08
Tonics, dressings and other hair grooming aids (rinse-off)	7.5	0.83	100	0.0083	0.0007	11.18
Tonics, dressings and other hair grooming aids (leave-on)	7.4	0.83	100	0.0083	0.0073	1.13
Hair tints	0.4	0.83	100	0.0083	0.0004	20.96
Hair rinses (coloring)	11	0.83	100	0.0083	0.0012	6.92
Hair shampoos (coloring)	6	0.83	300	0.0028	0.0010	2.71
Bath soaps and detergents	15	0.83	300	0.0028	0.0002	18.44
Other personal cleanliness products (liquid hand soap)	15	0.83	100	0.0083	0.0030	2.77
Shaving cream	4.5	0.83	100	0.0083	0.0003	26.350
Skin cleansing (cold creams, cleansing lotions, liquids, and pads)	15	0.83	100	0.0083	0.0135	0.61

MCI/MI = Methylchloroisothiazolinone/Methylisothiazolinone; MOS = margin of safety; NESIL = no-expected-sensitization-induction-level. Shading indicates product categories that fall below a MOS of 1.

The LOEL for MCI/MI in a 28-day repeated-dose oral study in rats was 7.0 mg/kg bw/d, the highest dose that was tested. At this dose, a reduction of serum triglyceride levels was observed in males and induction of hepatic phase 1 xenobiotic metabolizing enzymes with subtle histological changes in the liver were observed in females. In a 13-week inhalation study of 14% MCI/MI in rats that followed OECD TG 413, MCI/MI was tested at up to 2.64 mg ai/m<sup>3</sup>. Based on the occurrence of rhinitis, the LOEL was 1.15 mg/m<sup>3</sup>. The NOEL was 0.34 mg/m<sup>3</sup>.

A trade name mixture containing MCI/MI (14% ai) and cosmetic products containing this mixture were mutagenic in an Ames test, with and without metabolic activation.

An HRIPT of a hand wash containing 12 ppm MCI/MI was not irritating or sensitizing in 50 volunteers. Provocative baseline patch tests and phototoxicity tests produced positive results in patients with suspected MCI/MI allergy. Numerous baseline and retrospective studies that included MCI/MI indicate that sensitization to this preservative occurs worldwide. Numerous case studies demonstrate sensitization to MCI/MI resulting from exposure to a wide range of materials, including personal care products, paints, glues, and cleaners. Peripheral airway dysfunction has been observed in patients in South Korea that were exposed to MCI/MI as an HD.

Skin sensitization induction risk assessments of MCI/MI in multiple personal care and cosmetic products using an NESIL of 0.83  $\mu\text{g}/\text{cm}^2$  found that some leave-on products (eg, colognes and toilet waters) with MCI/MI at the recommended safe concentration of 7.5 ppm may increase the risk of sensitization induction. In most rinse-off products, 15 ppm MCI/MI was not associated with a potential increase risk of skin sensitization induction.

## Discussion

This safety assessment is for the combination of MCI and MI as used in cosmetics. Based on the numerous sensitization studies and reports that became available since the original report was issued, this safety assessment was reopened to reassess the conclusion published in 1992.

The Panel noted the results of a QRA for skin sensitization performed by the CIR SSC. The results indicated that some leave-on products comprising MCI/MI at the recommended maximum safe concentration of 7.5 ppm may yet increase the risk of inducing dermal sensitization. In most rinse-off products, 15 ppm MCI/MI was not associated with a potential increased risk of skin sensitization induction. Individuals

**Table 4.** Quantitative Risk Assessment of MCI/MI at the Maximum Recommended Use Concentrations in Cosmetic Products.<sup>75</sup>

Product Category	Maximum Recommended Concentration of Use (ppm)	Weight of Evidence NESIL ( $\mu\text{g}/\text{cm}^2$ )	SAF	AEL ( $\mu\text{g}/\text{cm}^2/\text{d}$ )	CEL ( $\mu\text{g}/\text{cm}^2/\text{d}$ )	Margin of Safety (AEL/CEL)
Baby shampoo	15	0.83	300	0.0028	0.0030	0.92
Bath soaps and detergents	15	0.83	300	0.0028	0.0002	18.44
Bubble baths	15	0.83	100	0.0083	0.0030	2.77
Hair conditioners	15	0.83	100	0.0083	0.0030	2.77
Permanent waves	15	0.83	100	0.0083	0.0630	0.13
Rinses (non-coloring)	15	0.83	300	0.0028	0.0026	1.08
Shampoos (non-coloring)	15	0.83	300	0.0028	0.0026	1.08
Tonics, dressings and other hair grooming aids (rinse-off)	15	0.83	100	0.0083	0.0015	5.59
Hair tints	15	0.83	100	0.0083	0.0149	0.56
Hair rinses (coloring)	15	0.83	100	0.0083	0.0030	2.77
Hair shampoos (coloring)	15	0.83	300	0.0028	0.0026	1.08
Other personal cleanliness products—liquid hand soap	15	0.83	100	0.0083	0.0030	2.77
Shaving cream	15	0.83	100	0.0083	0.0011	7.90
Skin cleansing (cold creams, cleansing lotions, liquids, and pads)	15	0.83	100	0.0083	0.0135	0.61
Cologne and toilet waters	7.5	0.83	100	0.0083	0.0166	0.50
Hair sprays (aerosol)	7.5	0.83	30	0.0277	0.0104	2.65
Hair sprays (pump)	7.5	0.83	30	0.0277	0.0165	1.68
Tonics, dressings and other hair grooming aids (leave-on)	7.5	0.83	100	0.0083	0.0074	1.12

AEL = acceptable exposure level; CEL = consumer exposure level; MCI/MI = Methylchloroisothiazolinone/Methylisothiazolinone; MOS = margin of safety; NESIL = no-expected-sensitization-induction-level; SAF = sensitization assessment factor.

Shading indicates product categories that fall below a MOS of 1.

previously sensitized to MCI/MI should avoid products that contain this ingredient mixture.

MCI/MI is a useful and necessary preservative system in cosmetic products. The Panel is aware that the conclusion herein differs from that reached by counterparts in the European Union. In part, the differing conclusions are based on interpretation of earlier LLNA data on which the hazard assessments were determined. However, the Panel supports managing sensitization risks by the use of valid assessment tools and strategies, such as a QRA system (or similar methodology). Instead of banning ingredients that may pose a risk under certain conditions (eg, formulation, body part exposure), the Panel has proposed that such risk-mitigating tools and strategies can be applied by formulators and thus avoid exhausting available preservative systems. Such systems are necessary to protect consumers from microbial contaminations that would otherwise occur in cosmetic products.

In response to concerns of reports of adverse events observed in infants following inhalation exposure to HDs that contained the MCI/MI preservative mixture, the Panel requested, and received, an inhalation study of at least 3 months in duration that is in accordance with the OECD TG 413. The Panel determined that the data mitigated concern for the use of this ingredient mixture at the reported concentrations in cosmetic products that could be incidentally inhaled following use. The concentrations used in the HD were orders of magnitude greater than those found in cosmetics.

## Conclusion

The Panel concluded that the ingredient mixture MCI/MI is safe in cosmetics when formulated to be nonsensitizing, based on the results of a QRA or similar methodology; however, at no point should concentrations exceed 7.5 ppm in leave-on products or 15 ppm in rinse-off products.

## Authors' Note

Unpublished sources cited in this report are available from the Director, Cosmetic Ingredient Review, 1620 L Street, NW, Suite 1200, Washington, DC 20036, USA.

## Author Contribution

Burnett, C. contributed to conception and design; contributed to acquisition, analysis, and interpretation; drafted the manuscript, and critically revised the manuscript, Bergfeld, W., Belsito, D., Peterson, L., Klaassen, C., Liebler, D., Marks, J., Shank, R., Slaga, T., and Snyder, P. contributed to conception and design, contributed to analysis and interpretation, and critically revised the manuscript. Heldreth, B. contributed to design, contributed to analysis and interpretation, and critically revised the manuscript. All authors gave final approval and agrees to be accountable for all aspects of work ensuring integrity and accuracy.

## Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The articles in this supplement were sponsored by the Cosmetic Ingredient Review. The Cosmetic Ingredient Review is financially supported by the Personal Care Products Council.

## References

1. Elder RL. Final report on the safety assessment of methylisothiazolinone and methylchloroisothiazolinone. *JACT*. 1992;11(1):75-128.
2. Nikitakis J, Kowcz A. wINCI: international cosmetic ingredient dictionary and handbook. Last Updated 2019. Accessed February 7, 2019. <http://webdictionary.personalcarecouncil.org/jsp/home.jsp>
3. Burnett CL, Boyer II, Bergfeld WF, et al. Amended safety assessment of methylisothiazolinone as used in cosmetics. *Int J Toxicol*. 2019;38(suppl 1):70S-84S. <https://online.personalcarecouncil.org/ctfa-static/online/lists/cir-pdfs/PR646.pdf>
4. U.S. Food and Drug Administration Center for Food Safety & Applied Nutrition (CFSAN). *Voluntary Cosmetic Registration Program - Frequency of Use of Cosmetic Ingredients*. Obtained under the Freedom of Information Act from CFSAN; requested as Frequency of Use Data. Published January 3, 2019. Accessed February 13, 2019.
5. Personal Care Products Council. Concentration of use by FDA product category - MCI/MI (ratio approximately 3:1). Unpublished data submitted by the Personal Care Products Council on May 2, 2019.
6. European Union. Regulation (EC) No. 1223/2009 of the European parliament and of the council of 30 November 2009 on cosmetic products. Published 2009. Accessed November 9, 2017. <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:342:0059:0209:en:PDF>
7. Scientific Committee on Consumer Safety (SCCS). *Opinion on the Mixture of 5-Chloro-2-Methylisothiazolin-3(2H)-one and 2-Methylisothiazolin-3(2H)-One*. European Commission; Published 2009. Accessed February 7, 2019. [https://ec.europa.eu/health/scientific\\_committees/consumer\\_safety/docs/sccs\\_o\\_009.pdf](https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_009.pdf). Report No. SCCS/1238/09
8. European Union. Commission regulation (EU) 2016/1198 of 22 July 2016 amending annex V to regulation (EC) No. 1223/2009 of the European parliament and of the council on cosmetic products. Published 2016. Accessed September 23, 2019. <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R1198&from=EN>
9. Thomsen AV, Schwensen JF, Bossi R, et al. Isothiazolinones are still widely used in paints purchased in five European countries: a follow-up study. *Contact Dermatitis*. 2017;78(4):246-253.
10. Schettgen T, Kraus T. Urinary excretion kinetics of the metabolite N-methylmalonic acid (NMMA) after oral dosage of chloromethylisothiazolinone and methylisothiazolinone in human volunteers. *Arch Toxicol*. 2017;91(12):3835-3841.
11. Pelletier G, Valli VE, Rigden M, Poon R. Effects of a 28-day oral exposure to a 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one biocide formulation in sprague-dawley rats. *Drug Chem Toxicol*. 2014;37(2):149-155.
12. Anonymous. 13-week inhalation toxicity study in rats (1984): study summary. Unpublished data submitted by the Personal Care Products Council on November 22, 2019.
13. Connor TH, Tee PG, Afshar M, Connor KM. Mutagenicity of cosmetic products containing Kathon. *Environ Mol Mutagen*. 1996;28(2):127-132.
14. Cantor Research Laboratories, Inc. 50 human subject repeat insult patch test skin irritation/sensitization evaluation (open patch; hand wash containing 12 ppm MCI/MI). Unpublished data submitted by the Personal Care Products Council on May 1, 2019.
15. Isaksson M, Gruvberger B, Goncalo M, Goossens A, Le Coz CJ, Bruze M. Repeated open application test with methylisothiazolinone in individuals sensitive to methylchloroisothiazolinone/methylisothiazolinone. *Contact Dermatitis*. 2014;70(4):244-246.
16. Aerts O, Goossens A, Marguery MC, et al. Photoaggravated allergic contact dermatitis and transient photosensitivity caused by methylisothiazolinone. *Contact Dermatitis*. 2017;78(4):241-245.
17. Isaksson M, Hauksson I, Hindsen M, Pontén A, Svedman C, Bruze M. Methylisothiazolinone contact allergy is rising to alarming heights also in southern Sweden. *Acta Derm Venereol*. 2015;95(1):31-34.
18. Stingeni L, Bianchi L, Foti C, et al. An Italian multicentre study on methylchloroisothiazolinone/methylisothiazolinone contact sensitivity: understanding the structure-activity relationship. *Contact Dermatitis*. 2018;78(4):297-299.
19. Czarnobilska E, Obtulowicz K, Dyga W, Wsolek-Wnek K, Spiewak R. Contact hypersensitivity and allergic contact dermatitis among school children and teenagers with eczema. *Contact Dermatitis*. 2009;60(5):264-269.
20. Urwin R, Warburton K, Carder M, Turner S, Agius R, Wilkinson SM. Methylchloroisothiazolinone and methylisothiazolinone contact allergy: an occupational perspective. *Contact Dermatitis*. 2015;72(6):381-386.
21. Boonchai W, Maneeprasopchoke P, Chaweekulrat P, Kasemsarn P. Associated factors of widespread pattern of dermatitis among patch test population: 12-Year retrospective study. *Australas J Dermatol*. 2018;60(1):e40-45.
22. Zirwas MJ, Hamann D, Warshaw EM, et al. Epidemic of isothiazolinone allergy in North America: prevalence data from the North American contact dermatitis group, 2013-2014. *Dermatitis*. 2017;28(3):204-209.
23. DeKoven JG, Warshaw EM, Belsito DV, et al. North American contact dermatitis group patch test results 2013-2014. *Dermatitis*. 2017;28(1):33-46.
24. Agullo-Perez A-D, Hervella-Garces M, Oscoz-Jaime S, Azcona-Rodríguez M, Larrea-García M, Yanguas-Bayona JI. Perianal dermatitis. *Dermatitis*. 2017;28(4):270-275.
25. Ali FR, Shepherd EL, Yell LC, Buckley DA, Williams JD. Escalating methylisothiazolinone/methylchloroisothiazolinone allergy probably attributable to methylisothiazolinone in leave-on body cosmetics. *Contact Dermatitis*. 2014;70(5):316-317.
26. Urwin R, Craig S, Latheef F, Wilkinson M. Methylisothiazolinone: the epidemic is declining - but not gone. *Contact Dermatitis*. 2017;76(5):301-302.

27. Amsler E, Aerts O, Raison-Peyron N, et al. Airborne allergic contact dermatitis caused by isothiazolinones in water-based paints: a retrospective study of 44 cases. *Contact Dermatitis*. 2017;77(3):163-170.
28. Dararattanaraj W, Pootongkam S, Rojanawatsirivej N, Wongpiyabovorn J. Patterns and risk factors of causative contact allergens in Thai adult patients with contact dermatitis. *Asian Pac J Allergy Immunol*. 2017;35(1):27-32.
29. Salman A. Methylchloroisothiazolinone and methylisothiazolinone contact allergy: a retrospective cohort study from a tertiary dermatology clinic in Turkey. *Contact Dermatitis*. 2019;80(3):193-194.
30. Craig S, Urwin R, Latheef F, Wilkinson M. Patch test clinic experience of potential cross-reactivity of isothiazolinones. *Contact Dermatitis*. 2017;76(5):299-300.
31. Yu SH, Sood A, Taylor JS. Patch testing for methylisothiazolinone and methylchloroisothiazolinone-methylisothiazolinone contact allergy. *JAMA Dermatol*. 2016;152(1):67-72.
32. Engfeldt M, Ale I, Andersen KE, et al. Multicenter patch testing with methylchloroisothiazolinone/methylisothiazolinone in 100 and 200 ppm within the international contact dermatitis research group. *Dermatitis*. 2017;28(3):215-218.
33. Veverka KK, Hall MR, Yiannias JA, et al. Trends in patch testing with the mayo clinic standard series, 2011-2015. *Dermatitis*. 2018;29(6):310-315.
34. Vauhkala A-R, Pesonen M, Suomela S, Kuuliala O, Suuronen K, Aalto-Korte K. Occupational contact allergy to methylchloroisothiazolinone/methylisothiazolinone and methylisothiazolinone. *Contact Dermatitis*. 2015;73(3):150-156.
35. Leiva-Salinas M, Frances L, Main-Cabanas I, Bouret AM, Silvestre JF. Methylchloroisothiazolinone/methylisothiazolinone and methylisothiazolinone allergies can be detected by 200 ppm of methylchloroisothiazolinone/methylisothiazolinone patch test concentration. *Dermatitis*. 2014;25(3):130-134.
36. Warshaw EM, Aschenbeck KA, Zug KA, et al. Wet wipe allergens: retrospective analysis from the North American contact dermatitis group 2011-2014. *Dermatitis*. 2017;28(1):64-69.
37. Ponten A, Bruze M, Engfeldt M, Hauksson I, Isaksson M. Concomitant contact allergies to formaldehyde, methylchloroisothiazolinone/methylisothiazolinone, methylisothiazolinone, and fragrance mixes I and II. *Contact Dermatitis*. 2016;75(5):285-289.
38. Gallo R, Signori A, Gervasio S, Riva S, Parodi A. Methylisothiazolinone contact allergy - are rinse-off cosmetics and household products relevant sources of exposure? *Contact Dermatitis*. 2016;75(5):319-321.
39. Puangpet P, Chawarug A, McFadden JP. Methylchloroisothiazolinone/methylisothiazolinone and methylisothiazolinone allergy. *Dermatitis*. 2015;26(2):99-102.
40. Murad A, Marren P. Prevalence of methylchloroisothiazolinone and methylisothiazolinone contact allergy in facial dermatitis: a single centre Irish study. *J Eur Acad Dermatol Venereol*. 2016;30(1):60-62.
41. Janach M, Kuhne A, Seifert B, French LE, Ballmer-Weber B, Hofbauer GF. Changing delayed-type sensitizations to the baseline series allergens over a decade at the Zurich University hospital. *Contact Dermatitis*. 2010;63(1):42-48.
42. Higgins E, Kirby B, Rogers S, Collins P. Methylchloroisothiazolinone and methylisothiazolinone allergic contact dermatitis and the effect of patch test concentration. *Dermatitis*. 2013;24(2):73-76.
43. Warshaw EM, Maibach HI, Taylor JS, et al. North American contact dermatitis group patch test results: 2011-2012. *Dermatitis*. 2015;26(1):49-59.
44. Mose AP, Lundov MD, Zachariae C, et al. Occupational contact dermatitis in painters - an analysis of patch test data from the danish contact dermatitis group. *Contact Dermatitis*. 2012;67(5):293-297.
45. Rios Scherrer MA, Rocha VB. Increasing trend of sensitization to methylchloroisothiazolinone/methylisothiazolinone (MCI/MI). *An Bras Dermatol*. 2014;89(3):527-528.
46. Ponyai G, Nemeth I, Temesvari E. Methylchloroisothiazolinone/methylisothiazolinone and methylisothiazolinone sensitivity in hungary. *Dermatol Res Pract*. 2016;2016(4579071):1-5.
47. Schwensen JF, Menne T, Andersen KE, Sommerlund M, Johansen JD. Occupations at risk of developing contact allergy to isothiazolinones in danish contact dermatitis patients: results from a danish multicentre study (2009-2012). *Contact Dermatitis*. 2014;71(5):295-302.
48. Gimenez-Arnau AM, Deza G, Bauer A, et al. Contact allergy to preservatives: ESSCA results with the baseline series, 2009-2012. *J Eur Acad Dermatol Venereol*. 2017;31(4):664-671.
49. Akan A, Toyran M, Vezir E, et al. The patterns and clinical relevance of contact allergen sensitization in a pediatric population with atopic dermatitis. *Turk J Med Sci*. 2015;45(6):1207-1213.
50. Alinaghi F, Bennike NH, Egeberg A, Thyssen JP, Johansen JD. Prevalence of contact allergy in the general population: a systemic review and meta-analysis. *Contact Dermatitis*. 2019;80(2):77-85.
51. Wolf R, Orion E, Matz H. Co-existing sensitivity to metronidazole and isothiazolinone. *Clin Exp Dermatol*. 2003;28(5):506-507.
52. Kujala V, Niinimäki A. Occupational induction of hypersensitivity after an accidental exposure to chloromethylisothiazolinone and methylisothiazolinone (CMI/MI) in an industrial worker. *Occup Med (Lond)*. 1999;49(1):51-53.
53. Cordoba S, Garcia-Donoso C, Villanueva CA, Borbujo J, Moreno A. Allergic contact dermatitis from methylisothiazolinone, with acute exanthematous pustulosis-like histopathologic changes. *Dermatitis*. 2011;22(1):60-61.
54. Ducharme O, Labadie M, Briand SM, Milpied B. Allergic contact dermatitis in a child caused by isothiazolinones in a noise putty. *Contact Dermatitis*. 2018;79(6):393-394.
55. Concha-Garzon MJ, Solano-Lopez G, Montes A, Fraga J, Sánchez J. Follicular allergic contact dermatitis due to methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) in a rinse-off soap product. *Clin Exp Dermatol*. 2015;40(6):690-691.
56. Finkbeiner H, Kleinhans D. Airborne allergic contact dermatitis caused by preservatives in home-decorating paints. *Contact Dermatitis*. 1994;31(4):275-276.

57. Hunter KJ, Shelley JC, Haworth AE. Airborne allergic contact dermatitis to methylchloroisothiazolinone/methylisothiazolinone in ironing water. *Contact Dermatitis*. 2008;58(3):183-184.
58. Jensen JM, Harde V, Brasch J. Airborne contact dermatitis to methylchloroisothiazolinone/methylisothiazolinone in a boy. *Contact Dermatitis*. 2006;55(5):311.
59. Corazza M, Amendolagine G, Cristofaro D, et al. Occupational allergic contact dermatitis caused by isothiazolinones in ultrasound gel: 2 cases. *Contact Dermatitis*. 2017;77(5):325-351.
60. Gardner KH, Davis MDP, Richardson DM, Pittelkow MR. The hazards of moist toilet paper. *Arch Dermatol*. 2010;145(8):886-890.
61. Todberg T, Opstrup MS, Johansen JD, Hald M. Occupational facial contact dermatitis caused by methylchloroisothiazolinone/methylisothiazolinone in a stainless steel aerosol spray. *Contact Dermatitis*. 2017;77(3):173-174.
62. Zhang AJ, Boyd AH, Asch S, Warshaw EM. Allergic contact dermatitis to slime: the epidemic of isothiazolinone allergy encompasses school glue. *Pediatr Dermatol*. 2018;36(1):e37-e38.
63. Andersson AM, Opstrup MS, Zachariae C, Friis UF, Thyssen JP, Johansen JD. The importance of a complete declaration of isothiazolinones in products beyond cosmetics. *Contact Dermatitis*. 2017;77(3):171-172.
64. Sechi A, Vincenzi C, Tengattini V, Piraccini BM, Neri I, La Placa M. Airborne dermatitis in a child caused by isothiazolinones in a water-based paint in Italy: call for better regulations. *Contact Dermatitis*. 2018;79(1):45-46.
65. Vincenzi C, Ravaioli GM, Lambertini M, et al. Allergic contact dermatitis caused by glitter glue used as make-up containing methylchloroisothiazolinone. *Contact Dermatitis*. 2019;80(2):128-130.
66. Maor D, Nixon R. Allergic contact dermatitis to methylchloroisothiazolinone/methylisothiazolinone in cooling tower technicians. *Dermatitis*. 2015;26(1):62-64.
67. Verdelli A, Francalanci S, Palleschi GM. Contact allergic dermatitis due to kathon CG contained in ultrasound gel. *Dermatitis*. 2014;25(1):35-36.
68. Raffi J, Adegunle L, Abitbol R. Allergic dermatitis to methylchloroisothiazolinone/methylisothiazolinone masquerading as pinworm infection. *Dermatitis*. 2019;30(5):323-324.
69. Cho HJ, Park DU, Yoon J, et al. Effects of a mixture of chloromethylisothiazolinone and methylisothiazolinone on peripheral airway dysfunction in children. *PLoS One*. 2017;12(4):e0176083.
70. Park DU, Ryu SH, Lim HK, et al. Types of household humidifier disinfectant and associated risk of lung injury (HDLI) in South Korea. *Sci Total Environ*. 2017;596-597:53-60.
71. Lee E, Son SK, Yoon J, et al. Two cases of chloromethylisothiazolinone and methylisothiazolinone-associated toxic lung injury. *J Korean Med Sci*. 2018;33(16):e119.
72. Lee SY, Park DU, Do KH, Jang SJ, Hong SJ. The pathological findings of chloromethylisothiazolinone and methylisothiazolinone-associated lung injury. *J Korean Med Sci*. 2019;34(14):e102.
73. Towle KM, Drechsel DA, Warshaw EM, et al. Risk assessment of the skin sensitization induction potential of kathon CG in rinse-off and leave-on personal care and cosmetic products. *Dermatitis*. 2018;29(3):132-138.
74. Kim MK, Kim KB, Lee JY, et al. Risk assessment of 5-chloro-2-methylisothiazol-3(2H)-one/2-methylisothiazol-3(2H)-One (CMIT/MIT) used as a preservative in cosmetics. *Toxicol Res*. 2019;35(2):103-117.
75. CIR Science and Support Committee of the personal care products council. Quantitative risk assessment for allergic contact dermatitis: methylisothiazolinone/methylchloroisothiazolinone as used in cosmetics. Unpublished data submitted by the Personal Care Products Council on May 2, 2019.